HIMS — Hims & Hers Health Share News
0.000.00%
Last trade - 00:00- $6.85bn
- $7.38bn
- $2.35bn
Hims & Hers Health, Inc. reports results for the quarter ended June 30 - Earnings Summary
Hims and Hers gains on forecast raise, higher quarterly revenue
Hims & Hers' shift to branded obesity drugs drives wider quarterly loss (updated)
Telehealth platform Hims & Hers swings to Q2 net loss as margin pressure offsets revenue growth
Hims & Hers posts higher quarterly revenue on strong subscriber growth
U.S. STOCKS ON THE MOVE-Mondelez, IDEX, Merchants Bancorp
US FTC sues Hims & Hers for sending user health info to Meta, Snap (updated)
Brief: Hims & Hers Says FTC Lawsuit Disregards Substantial Evidence We Provided The Agency During Investigation
Hims & Hers falls after report US FTC suing co for sending user health info to Meta, Snap
US FTC suing Hims & Hers for sending user health info to Meta, Snap
FDA advisers back first four of seven unapproved peptides under review for looser rules (updated)
U.S. STOCKS ON THE MOVE-Allegion, First Citizens, Hims & Hers
Hims gains after FDA panel votes to place popularly used peptide BPC-157 on compounding list
FDA panel votes to place popular peptide BPC-157 on compounding list
US FDA advisers weigh restrictions on seven peptides as industry presses for expansion
Analysis: Hims & Hers stands to gain if the FDA loosens restrictions on peptides
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Corrected: ANALYSIS-Hims' obesity drug business may get boost as employers drop coverage
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending